Lv5
910 积分 2023-11-24 加入
A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)
2天前
已完结
Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
3天前
已完结
HIV immune evasin Nef enhances allogeneic CAR T cell potency
22天前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
23天前
已完结
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
24天前
已完结
Novel strategies to manage CAR-T cell toxicity
26天前
已完结
IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells
2个月前
已完结
Engineered receptors for soluble cellular communication and disease sensing
3个月前
已完结
The PROTAC gold rush
3个月前
已完结
Engineered receptors for soluble cellular communication and disease sensing
4个月前
已完结
皖公网安备34019202002308
